Oral compositions for animals

Abstract

The present disclosure aims to provide an oral composition for animals that can improve the oral environment of animals. [Solution] The present disclosure provides an oral composition for animals comprising Pleurotus cornucopiae and a plant of the genus Sasa. The oral composition for animals according to claim 1, wherein the Pleurotus cornucopiae is an extract of Pleurotus cornucopiae. The oral composition for animals according to claim 1, wherein the plant of the genus Sasa includes Sasa senanensis and / or Sasa kurilensis. The oral composition for animals according to claim 1, wherein the plant of the genus Sasa is an extract of a plant of the genus Sasa.

Description

[Technical Field]

[0001] The present disclosure relates to oral compositions for animals. [Background technology]

[0002] In recent years, pet animals such as cats and dogs have been experiencing an increase in lifestyle-related diseases, just like humans, due to factors such as their dietary habits being similar to humans. Among these, the increase in oral diseases such as gingivitis, periodontitis, alveolar pyorrhea, stomatitis, dental caries, and halitosis has become a problem. One of the causes of these oral diseases is thought to be the accumulation of food debris in the mouth, which causes calcium and other substances in saliva to deposit on the surface of the teeth, forming tartar. If oral disease develops, the symptoms can cause bad breath, which can affect the relationship with the owner.

[0003] Therefore, as a treatment method for oral diseases, when the accumulation of tartar increases and the symptoms in the oral cavity worsen, treatment such as tartar removal is performed under general anesthesia. However, general anesthesia places a great burden on the animal's body. Another method of treatment and prevention is for pet owners to routinely scrub the teeth with toothpaste and a toothbrush, gauze, etc. However, this method has problems such as being difficult for pets to treat adequately due to its reluctance to do so, its time-consuming nature, and the owner's inexperience with it. To address these issues, various types of brushes, ropes, textured toys, hard snacks, dry food with oral cleansing properties, and the like are commercially available, allowing pets to chew on them to clean their teeth. These products reduce the burden on pet owners because the pets themselves clean their teeth. However, brushes, ropes, and textured toys no longer provide sufficient effectiveness if the pet becomes bored with them. As described above, since it is difficult for pets to brush their teeth like humans do, there is a demand for drugs that can suppress or treat oral diseases such as gingivitis.

[0004] For example, Patent Document 1 discloses that an extract extracted from noni fruit is blended into jelly, agar, candy, and tablet-type pet food as an ingredient for improving the oral environment.

[0005] Furthermore, Patent Document 2 discloses a method of applying sodium hexametaphosphate to the surface of dry food and feeding it to pets. However, the effect is insufficient, and therefore, there is a need for drugs that can suppress or treat oral diseases such as gingivitis. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Laid-Open No. 2007-089414 [Patent Document 2] Special Publication No. 07-507927 Summary of the Invention [Problem to be solved by the invention]

[0007] The present disclosure aims to provide an oral composition for animals that can improve the oral environment of animals. [Means for solving the problem]

[0008] As a result of extensive research, the present inventors have surprisingly discovered that a composition containing Pleurotus cornucopiae and a plant of the genus Sasa is effective against oral diseases in animals, and have thus completed the present invention.

[0009] That is, the present disclosure is as follows. Section 1. An oral composition for animals comprising Pleurotus cornucopiae and a plant of the genus Sasa. Section 2. Item 2. The oral composition for animals according to Item 1, wherein the maitake mushroom is an extract of maitake mushroom. Section 3. Item 2. The oral composition for animals according to Item 1, wherein the Sasa plant includes Sasa senanensis and / or Sasa kurilensis. Section 4. Item 2. The oral composition for animals according to Item 1, wherein the plant of the genus Sasa is an extract of Sasa. Section 5. Item 1. An oral composition for animals according to Item 1, for intraoral use to treat at least one oral disease selected from the group consisting of periodontitis, gingivitis, periodontal disease, alveolar pyorrhea, stomatitis, and halitosis. Section 6. Item 1. The oral composition for animals according to Item 1, which is for immunomodulation. Section 7. Item 7. The oral composition for animals according to Item 6, wherein the immunomodulation is caused by suppressing the production of inflammatory cytokines. Section 8. Item 8. The oral composition for animals according to Item 7, wherein the inflammatory cytokine is interleukin-1β (IL-1β). Section 9. Item 1. An oral composition for animals according to Item 1, for improving the intestinal environment. Section 10. Item 10. The oral composition for animals according to Item 9, which is for suppressing the odor of excrement. Section 11. Item 1. The oral composition for animals according to Item 1, which is for use in foods and beverages, cosmetics, pharmaceuticals, or quasi-drugs. Section 12. Item 1. A food or drink containing the oral composition for animals according to Item 1. Section 13. Item 1. A feed containing the oral composition for animals according to Item 1. Section 14. Item 1. A pet food containing the oral composition for animals according to Item 1. Section 15. Item 1. A pharmaceutical or quasi-drug containing the oral composition for animals according to Item 1. [Effects of the Invention]

[0010] According to the present disclosure, an oral composition for animals that can improve the oral environment of animals can be provided. The oral composition for animals can also improve the intestinal environment of animals. [Brief explanation of the drawings]

[0011] [Figure 1] FIG. 1 shows a photograph (left) of a cat suffering from severe gingivitis before administration of the veterinary oral composition of Example 1 of the present disclosure, and a photograph (right) of the cat after eight administrations. [Figure 2] FIG. 2 is a graph showing the amount of change in gingival index (GI) for the veterinary oral compositions of Examples 1 and 2 of the present disclosure and Comparative Example 1 (control group). [Figure 3] FIG. 3 shows the results of a questionnaire survey conducted on owners asking whether their dog's bad breath was reduced after administration of the veterinary oral composition of Example 3 of the present disclosure. [Figure 4] FIG. 4 is a graph showing a comparison (synergistic effect) of the amount of change in gingival index (GI) between the oral composition for animals of Example 4 and Comparative Example 2 (single agent) in the present disclosure. [Figure 5] FIG. 5 shows the results of a questionnaire survey conducted on owners asking whether the odor of their dog's stool was reduced after administration of the veterinary oral composition of Example 5 of the present disclosure. [Figure 6] FIG. 6 shows the results of a questionnaire survey conducted on cat owners regarding whether the odor of their cat's feces was reduced after administration of the oral composition for animals of Example 5 of the present disclosure. DETAILED DESCRIPTION OF THE INVENTION

[0012] The oral composition for animals of the present disclosure will be described in detail below. Here, the oral composition for animals of the present disclosure may also be simply referred to as an oral composition. Composition for animal oral cavity The oral composition for animals of the present disclosure contains Pleurotus cornucopiae and a plant of the genus Sasa.

[0013] Tamogitake mushroom The oral composition for animals of the present disclosure contains Pleurotus cullet as an active ingredient together with a plant of the genus Sasa. Tamogitake (scientific name: Pleurotus cornucopiae var. citrinopileatus) is a mushroom belonging to the genus Pleurotus (scientific name: Pleurotus cornucopiae), which belongs to the Basidiomycetes subdivision, Euthybasidiomycetes subdivision, Pleurotus cornucopiae subdivision, Pleurotus order, Pleurotus family, Pleurotus genus. Tamogitake is characterized by its bright yellow cap and is widely eaten, mainly in Hokkaido. Tamogitake is also called Tamogitake (Tamogitake).

[0014] In the present disclosure, the maitake mushroom may be naturally occurring or artificially cultivated. The maitake mushroom may be raw, or may be processed after harvesting, such as dried or dried and then powdered.

[0015] In addition, the veterinary oral composition of the present disclosure can use an extract of Tamogitake (Tamogitake extract) as Tamogitake. Examples of the Tamogitake extract include an aqueous solvent extract of Tamogitake and an organic solvent extract of Tamogitake. The Pleurotus cornucopiae extract is preferably an aqueous solvent extract of Pleurotus cornucopiae. The aqueous solvent extract of Pleurotus cornucopiae refers to a mixture of one or more substances selected from liquid, semi-solid, or solid substances containing components extracted from Pleurotus cornucopiae using an aqueous solvent.

[0016] Here, in the present disclosure, the aqueous solvent is not particularly limited as long as it is a solvent mainly composed of a polar solvent, and may consist of one type of solvent or may be a mixture of two or more types of solvents.

[0017] Examples of such polar solvents include water, methanol, ethanol, acetic acid, formic acid, 1-butanol, 1-propanol, 2-propanol, etc. As the polar solvent, water is preferred.

[0018] In the present disclosure, the aqueous solvent may be prepared by mixing or dissolving a suitable solute in water or an aqueous solvent in advance. Examples of such aqueous solvents include water mixed with or dissolved in citric acid, water mixed with or dissolved in sodium bicarbonate, and salt mixed with or dissolved in acetic acid. Preferred aqueous solvents are citric acid aqueous solution, sodium bicarbonate aqueous solution, and salt-acetic acid solution. In the present disclosure, the aqueous solvent may be acidic, neutral, or basic. The temperature of the aqueous solvent is also not particularly limited as long as its function is not impaired, and may be low, normal temperature, or high temperature. In the present disclosure, hot water can be used as a suitable aqueous solvent.

[0019] In the present disclosure, the aqueous solvent extract of Pleurotus cornucopiae can be produced by a conventional method, for example, by adding Pleurotus cornucopiae to an aqueous solvent, heating or crushing and stirring, and then separating the solid and liquid components by filtration or the like, and recovering the liquid component.

[0020] Specifically, active ingredients are extracted from harvested coral reef mushrooms. The extraction is preferably carried out by hot water extraction. For example, harvested coral reef mushrooms are placed in boiling water in an amount 2 to 30 times, preferably 5 to 20 times, the weight of the coral reef mushroom, and stirred while adding steam. After boiling, an aqueous solvent extract is extracted with stirring for 10 minutes. The resulting aqueous solvent extract may be used as is, or may be filtered to remove solids. The produced aqueous solvent extract of coral reef mushrooms may also be subjected to ultrafiltration, ultrasonic treatment, etc. Such ultrafiltrates (filtrate and residue), ultrasonic treatment products, etc., are also included in the aqueous solvent extract of coral reef mushrooms. The aqueous solvent extract of Pleurotus cornucopiae may be appropriately concentrated using a vacuum concentrator, freeze concentrator, etc. To preserve the aqueous solvent extract of Pleurotus cornucopiae for a long period of time, it may be sealed in a retort pack and then sterilized, for example, at 120°C for 15 minutes, or may be powdered by freeze-drying or spray-drying.

[0021] Commercially available extracts of Tamogitake mushrooms include, for example, Biogod (registered trademark, Three B Co., Ltd.). Tamogitake mushroom extracts can also be called Tamogitake extract, Tamogitake extract, Tamogitake extract solution, etc.

[0022] Examples of the pulverization method include crushing with a roll pulverizer or the like, cutting with a food processor or the like, grinding with a ball mill pulverizer or the like, and pulverizing by impact with a hammer pulverizer or the like. Examples of the purification method include filtration, distillation, recrystallization, reprecipitation, and methods using various types of chromatography. Examples of the concentration method include boiling concentration, vacuum concentration (reduced pressure concentration) using an evaporator or the like, freeze concentration, and membrane concentration using a reverse osmosis membrane or the like. Examples of the sterilization method include a method using an autoclave, a high-frequency wave method, and a filter filtration method.

[0023] For example, the aqueous solvent extract of Pleurotus cornucopiae includes at least an extraction step of extracting Pleurotus cornucopiae extract to obtain an extract, and a concentration step of concentrating the extracted extract. Furthermore, the method may include a step of appropriately diluting the obtained concentrate depending on the intended use.

[0024] Ingredients contained in Tamogitake extract include β-D glucans, ergothioneine, etc.

[0025] Specifically, after harvesting Tamogitake mushrooms, if there is a sufficient amount, they are boiled in tap water brought to a boil at 100°C under 1 atmosphere for 30 minutes. If the harvest is insufficient, they are stored in the refrigerator and then combined with the next harvest and boiled in the same manner as above. After boiling, the filtered product is sent to a concentrator.

[0026] The concentration step for concentrating the extracted extract is not particularly limited, and can be performed using a known concentration device such as a flash concentration device (vacuum concentration). Specifically, the pressure can be reduced from 1 atmosphere, and the water can be distilled off by boiling at a lower boiling point. The concentration of the Pleurotus cornucopiae extract concentrate is not particularly limited, and is, for example, 0.1 to 50 Brix, and can be diluted according to the application.

[0027] bamboo grass The oral composition for animals of the present disclosure contains Pleurotus culeatus and a plant of the genus Sasa as active ingredients.

[0028] The genus Sasa used in the present disclosure is a plant belonging to the genus Sasa, subfamily Bambusoideae, family Poaceae. Examples of plants of the genus Sasa include plants of the sections Kurile, Nambusuzu, Amagisa, Chimakisa, Miyakosa, Kumazasa, etc. Examples of plants of the genus Sasa include Gotenba Sasa, Katsuragi Sasa, Suzudake, Miyayama Kuma Sasa, Nemagaridake, Miyako Sasa, Hosoba Sasa, Kuma Sasa, Kuma Sasa, and Chinese Sasa. Among these, Kuma Sasa is the most preferred.

[0029] Here, the Japanese bamboo grass (scientific name: Sasa senanensis (Fr. et Sav.) Rehder) belongs to the genus Sasa in the family Poaceae. Japanese bamboo grass is endemic to Japan and is a type of bamboo that belongs to the subfamily Bambusoideae of the family Poaceae, which is a relative of bamboo.

[0030] Other names (common names) for Kuma Sasa include Kuma Sasa, Kumai Sasa, and Kumai Sasa. Furthermore, there are many similar species of Kuma Sasa, leading to confusion in its classification, and bamboo species of the same genus as Kuma Sasa, such as Kurilensis (Sasa kurilensis), Sasamorpha borealis, Kuma Sasa (Sasa senanensis), Chimaki Sasa (Sasa palmata), and Miyako Sasa (Sasa niponica), are sometimes referred to as Kuma Sasa. Therefore, the plants of the genus Sasa in the Poaceae family, Bambusoideae subfamily of the present disclosure may include not just one of the plants listed above, but two or more species of bamboo.

[0031] The Sasa plant may be one that grows naturally or one that has been artificially cultivated. Furthermore, the Sasa plant may be a fresh plant, or may be one that has been harvested and then processed, such as one that has been dried or dried and then powdered.

[0032] The Sasa plant used in the oral composition for animals of the present disclosure can be an extract of a Sasa plant. The extract of a Sasa plant is preferably an aqueous solvent extract of a Sasa plant. Among these, an aqueous extract of Sasa collected in the Teshio mountain range in Hokkaido between July and October is preferred.

[0033] An example of a commercially available aqueous solvent extract of a plant of the genus Sasa is Rioherbal (registered trademark), a bamboo extract described in Patent No. 3983233. Extracts of plants of the genus Sasa can be referred to as Bambusoideae extract, Bambusoideae extract, Bambusoideae extract liquid, bamboo extract, bamboo extract liquid, bamboo extract, etc. The extract of the Sasa plant is not particularly limited, and examples thereof include those obtained by steaming the leaves and / or culms of a Sasa plant (or bamboo) in which the moisture content of the leaves and / or culms before steaming is 10% by mass or less relative to the total leaves and / or culms of the Sasa plant (or bamboo), at 160 to 190°C for 30 seconds to 1 hour with dry steam whose dryness has been increased using a pressure reducing valve and a gas-liquid separator, and then extracting with an aqueous solvent, and those obtained by steaming the bamboo raw material under high pressure and then extracting it with pressurized hot water.

[0034] The leaves and / or culms of the bamboo plant or bamboo used for steaming are preferably dried. The moisture content of the bamboo leaves and / or culms is preferably 10% or less. The bamboo leaves and / or culms used in the steaming process of the present invention are preferably in the form of fine pieces, with a preferred size of 0.5 to 20 mm.

[0035] The equipment used for steaming may be any equipment that can withstand high temperatures and pressures. The temperature during steaming is preferably 160 to 190°C. The time for steaming is preferably between 30 seconds and 1 hour, more preferably between 5 minutes and 20 minutes.

[0036] When the pressure is released after the end of the steaming process, it is preferable to quickly open the device to atmospheric pressure, as this will allow more destruction of the bamboo leaf or culm tissue and improve extraction efficiency.

[0037] The steam used for cooking is most preferably steam from a system equipped with a gas-liquid separator and pressure reducing valve in the steam piping connecting the steam source (e.g., a boiler) and the cooking equipment. Using such a system improves the dryness of the steam. The higher the dryness and the less steam condensate (called drain), the more efficiently specific components can be extracted and the more appropriately the amount of sugars extracted can be controlled. Because there is no easy method for measuring the dryness of steam, it is difficult to directly measure it in conventional manufacturing equipment. Therefore, to obtain dry steam, it is preferable to use a gas-liquid separator that has been confirmed to achieve a dryness of 99% or higher using a dryness measurement system owned by a gas-liquid separator manufacturer. Gas-liquid separators are available in centrifugal and baffle types, but the baffle type is preferred because it can achieve a stable high dryness regardless of the steam volume.

[0038] If air remains in the steaming apparatus during steaming, contact between the dry steam and the leaves or culms of the Sasa plant (or bamboo grass) is hindered, resulting in insufficient steaming and a decrease in extraction efficiency, which is undesirable. A means of preventing air from remaining in the steaming apparatus is to introduce steam with a manual or automatic air vent valve open to expel the air from the steaming apparatus. The steam temperature for expelling the air should be 80 to 200°C, preferably 100 to 180°C. The time for expelling the air is preferably 0.5 to 60 minutes.

[0039] The method of extraction with an aqueous solvent is not particularly limited. For example, after steaming, an aqueous solvent is added while cooling or maintaining the temperature, and the steamed bamboo leaves or culms are immersed in the aqueous solvent at room temperature to 180°C.

[0040] The aqueous solvent is preferably a water-soluble solvent such as methanol, ethanol, acetone, or an aqueous solution thereof, water, etc. If permitted depending on the use of the bamboo extract, the extraction efficiency can be increased by using an alkaline aqueous solution as the aqueous solvent. The alkaline aqueous solution is not particularly limited, and is preferably, for example, an aqueous solution of sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, ammonium hydrogen carbonate, or the like.

[0041] The steaming step and the extraction step may be repeatedly performed without departing from the scope of the present disclosure. In addition, other steps such as a holding step may be performed before or after each step.

[0042] The mechanism by which the phenylpropanoids, acetic acid, formic acid, and 3-hydroxypyridine contained in the extract of Sasa plants or Sasa extract exert their antibacterial or antimutagenic properties is not clear, but it is presumed that the synergistic effects of each component result in a greater effect than each component acting alone.

[0043] Phenylepropanoids contained in extracts of plants of the genus Sasa or Sasa extracts include coumaric acid, ferulic acid, caffeic acid, vanillin, etc. Coumaric acid is the most abundant, followed by ferulic acid. The total amount of all phenylpropanoids in the Sasa extract required for effective action as an antibacterial or antimutagenic agent needs to be 0.5 mg / g or more, and preferably, coumaric acid alone needs to be 1 mg / g or more to obtain high antibacterial and antimutagenic properties.

[0044] The content of acetic acid and formic acid contained in the Sasa plant extract or Sasa extract must each be 0.5 mg / g or more, preferably 5 mg / g or more of formic acid alone, and more preferably 10 mg / g or more of formic acid alone.

[0045] The detailed synthetic pathway of 3-hydroxypyridine contained in the extract of plants of the genus Sasa or the extract of Sasa is unknown, but it is presumed to be a substance produced when bamboo leaves and / or culms are steamed. The content of 3-hydroxypyridine required as an antibacterial or antimutagenic agent is 0.5 mg / g or more, preferably 1 mg / g or more, and more preferably 2 mg / g or more.

[0046] The sugars contained in the Sasa plant extract or the Sasa extract are monosaccharides and / or polysaccharides composed of xylose, arabinose, glucose, mannose, galactose, etc. When the heating residue is adjusted to 40 to 60 wt %, the sugar content is preferably 50 mg / g or less.

[0047] Phenylpropanoids, acetic acid, formic acid, and 3-hydroxypyridine can be quantified by liquid chromatography, gas chromatography, etc. Sugars can be quantified by ion chromatography.

[0048] The extract of a plant of the genus Sasa or the extract of Sasa of the present invention may be in the form of a solution or a solid, or may be a mixture with other compounds. In the case of a mixture, it may be processed by spray drying, freeze drying, addition of a bulking agent such as dextrin, etc. Furthermore, it may be a mixture that has undergone a selection process such as filtration, column purification, or solvent washing.

[0049] In the oral composition for animals of the present disclosure, the content of the Sasa plant is, for example, 0.1 to 10,000 parts by mass, preferably 1 to 1,000 parts by mass, more preferably 10 to 200 parts by mass, and particularly preferably 80 to 120 parts by mass per 100 parts by mass of Pleurotus pilchardus. In the animal oral cavity composition of the present disclosure, the content of the Sasa plant extract is, for example, 0.1 to 10,000 parts by mass, preferably 1 to 1,000 parts by mass, more preferably 10 to 200 parts by mass, and particularly preferably 80 to 120 parts by mass per 100 parts by mass of the Pleurotus ulmoides extract. In the oral composition for animals of the present disclosure, by including both Pleurotus cornucopiae and a plant of the genus Sasa, a synergistic effect (synergistic effect) can be achieved.

[0050] The oral composition for animals of the present disclosure may contain only the active ingredients, maitake mushroom and bamboo plants, or may further contain other optional ingredients as long as they do not interfere with the effects of the present disclosure. Optional ingredients The other optional components are not particularly limited, and examples thereof include pharmaceutically acceptable components (e.g., excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizers, suspending agents, etc.), components acceptable as foods (e.g., minerals, vitamins, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants, flavorings, stabilizers, preservatives, sustained-release regulators, surfactants, solubilizers, wetting agents, etc.), and biologically acceptable carriers.

[0051] Biologically acceptable carriers include carriers that are inert to the organisms to which the veterinary oral composition is administered. A biologically inert carrier means that the carrier does not interfere with normal biological functions, including metabolic, reproductive, motor, and neurological functions. For example, a biologically acceptable carrier includes components that are metabolized by the normal metabolic functions of an organism, as well as components that are not or are poorly digested or metabolized and do not interfere with the functions of the organism.

[0052] The oral composition for animals of the present disclosure can be in any form, such as a solid (powder), gel, or liquid. The oral composition for animals of the present disclosure can be made into a gel or liquid form by adding an appropriate solvent, such as water, to the dried composition at the time of ingestion. Furthermore, the oral composition for animals of the present disclosure can also be distributed in a frozen state.

[0053] Furthermore, the oral composition for animals of the present disclosure may additionally contain optional ingredients such as flavorings, colorings, flavoring agents, sweeteners, seasonings, etc., as needed. Also, known ingredients known to have preventive or therapeutic effects on periodontal disease may be combined with the oral composition for animals of the present disclosure. Furthermore, oral compositions for animals containing a chewable carrier may further contain plant fiber, etc., to achieve a tooth brushing effect.

[0054] In the oral composition for animals of the present disclosure, the content of Pleurotus cornucopiae and Sasa plant can be formulated so that it is usually about 0.03 to 0.07 g / dose, preferably about 0.04 to 0.06 g / day per animal. When the animal oral composition is incorporated into feed, the amount of maitake mushroom and bamboo plant to be incorporated into the feed can be determined based on the body weight of the animal to which the animal oral composition of the present disclosure is to be administered and the daily feed intake.

[0055] The veterinary oral composition of the present disclosure can achieve either or both of the effects of preventing and treating oral diseases by administering it to the oral cavity of an animal. That is, the present disclosure provides a method for either or both of the effects of preventing and treating oral diseases, comprising the step of administering a composition containing Pleurotus cornucopius and a plant of the genus Sasa to the oral cavity. In particular, a method for preventing or treating oral diseases, comprising the step of administering a composition containing Pleurotus cornucopius and a plant of the genus Sasa to the oral cavity of a human or non-human animal, is a preferred embodiment of the present disclosure. The composition of the present disclosure can be administered to the oral cavity of a mammal in any form, such as a solid, paste, gel, or liquid. A solid formulation can be administered via chewing or swallowing. A solid formulation can also be administered into the oral cavity as a lozenge (so-called troche). A paste or gel formulation can be administered by applying it to oral tissues in addition to chewing or swallowing. A liquid formulation can be administered by spraying it into the oral cavity, rinsing the mouth, or gargling in addition to swallowing.

[0056] The dosage of the oral composition for animals containing the presently disclosed maitake mushroom and bamboo plant can be appropriately set within the above range depending on the health condition of the animal ingesting it, the method of administration, and the combination with other agents, etc.

[0057] The oral composition for animals of the present disclosure may be administered once a day, or in multiple doses, such as twice a day or three times a day, as long as the daily amount of active ingredient is within the above-mentioned range.

[0058] The oral composition for animals of the present disclosure may be in any form, such as a solid (solid composition), liquid, or paste. The oral composition for animals of the present disclosure may be in the form of, for example, plain tablets, sugar-coated tablets, granules, powder, tablets, or capsules (hard capsules, soft capsules, seamless capsules, etc.). The oral composition for animals of the present disclosure can be prepared, for example, by mixing the active ingredients, Pleurotus cornucopius and a plant of the genus Sasa, with other ingredients as necessary, and molding the mixture into the above-mentioned dosage form.

[0059] animal Mammals to which the veterinary oral composition of the present disclosure can be administered include pet animals such as dogs and cats, mammals kept in zoos, and humans. Examples of mammals include pigs, wild boars, goats, sheep, horses, cows, deer, donkeys, reindeer, rabbits, monkeys, gorillas, orangutans, chimpanzees, sloths, elephants, giraffes, rhinoceroses, hippos, tapirs, wolves, hyenas, bears, pandas, red pandas, masked palm civets, foxes, raccoon dogs, raccoon dogs, tigers, lions, leopards, cheetahs, otters, seals, fur seals, sea lions, sea lions, dolphins, killer whales, whales, etc. Here, mammals also include humans. In the present disclosure, the oral composition for animals refers to a composition for administration into the oral cavity of the animal. The oral composition for animals of the present disclosure can also be referred to as an oral composition.

[0060] Purpose The oral compositions for animals according to the present disclosure can be used to improve, alleviate, prevent, or treat diseases or symptoms in the oral cavity. Specifically, oral diseases or symptoms thereof include periodontitis, gingivitis, periodontal disease, alveolar pyorrhea, stomatitis, halitosis, etc. In other words, the oral composition for animals of the present disclosure can be suitably used in oral care agents, for example, as an anti-inflammatory agent, etc. The oral composition for animals of the present disclosure can be rephrased as a periodontitis inhibitor, gingivitis inhibitor, periodontal disease inhibitor, alveolar pyorrhea inhibitor, stomatitis inhibitor, halitosis inhibitor, etc. Periodontitis is a disease that causes inflammation of the tissues that support the teeth (gums, alveolar bone, and other periodontal tissues), and is the result of gingivitis progressing. If not treated properly, the bone that supports the teeth can be destroyed, leading to tooth loss. Gingivitis is an inflammation of the gums (gingiva). It is the early stage of periodontal disease and is caused by plaque, resulting in swelling and bleeding. It is generally reversible with early treatment. Periodontal disease, synonymous with periodontitis, is a disease of the tissues that support the teeth. If gingivitis progresses, it becomes periodontitis, and if it progresses further, it can destroy the alveolar bone and cause tooth loss. Pyorrhea is a condition in which pus leaks from the gums due to the progression of periodontal disease. This is a serious stage in which the bone supporting the teeth has been significantly damaged, and early treatment is required. Stomatitis is inflammation or ulcers that occur in the mucous membranes of the oral cavity. Causes include stress, nutritional deficiencies, and a weakened immune system. Bad breath is often caused by oral problems such as periodontal disease, gingivitis, and stomatitis. It can also be caused by gastrointestinal problems, diet, and smoking. Furthermore, the symptoms in the oral cavity include various symptoms related to oral health problems or oral diseases, such as bleeding gums, redness, swelling, pus, pain, itching, stickiness in the mouth, etc.

[0061] Known pathogenic bacteria that cause the oral health problems or diseases include, for example, bacteria (microorganisms) of the genus Porphyromonas, such as Porphyromonas gingivalis; the genus Prevotella, such as Prevotella intermedia; and the genus Treponema, such as Treponema denticola. For example, since periodontal disease is caused by specific oral bacteria as described above, suppressing the number of these pathogenic bacteria is also included in the alleviation, prevention, or treatment of oral health problems or diseases.

[0062] The oral composition for animals of the present disclosure can be used as an immunomodulatory composition. The oral composition for animals of the present disclosure can also be referred to as an immunostimulating composition, etc. The oral composition for animals of the present disclosure can also be referred to as an immunomodulator, an immunostimulator, etc. Here, immune regulation is known to be induced by suppressing the production of inflammatory cytokines, which are not particularly limited and may be selected from the group consisting of interleukin-1α, interleukin-1β (IL-1β), interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interleukin-13, interleukin-14, interleukin-15, interleukin-16, interleukin-17, interleukin-18, and leukemia inhibitory factor (LIF).

[0063] The oral composition for animals according to the present disclosure can be used for improving the intestinal environment. The oral composition for animals according to the present disclosure can be rephrased as an agent for improving the intestinal environment.

[0064] The oral composition for animals according to the present disclosure can be used to suppress the odor of excrement. Examples of the odor of excrement include feces odor, urine odor, etc. The oral composition for animals according to the present disclosure can also be referred to as an excrement odor suppressant, a feces odor suppressant, etc.

[0065] The oral composition for animals according to the present disclosure can be used to improve the glossiness of an animal's coat. The oral composition for animals according to the present disclosure can also be referred to as an agent for improving the glossiness of an animal's coat.

[0066] Furthermore, the oral composition for animals according to the present disclosure can be used for applications such as food and drink, pharmaceuticals (including quasi-medical products), and cosmetics.

[0067] The oral composition for animals of the present disclosure can be used as a food or drink, a medicine (including quasi-drugs), or a cosmetic product itself, or can be added to a food or drink, a medicine, a quasi-drug, or a cosmetic product.

[0068] A food, drink, or pharmaceutical product (including quasi-drugs) comprising the oral composition for animals of the present disclosure, or a food, drink, or pharmaceutical product (including quasi-drugs) comprising the oral composition for animals of the present disclosure, may be for use in the oral cavity of an animal. "For use in the oral cavity" can be rephrased as "oral care."

[0069] food and drink The food and beverage products disclosed herein contain Pleurotus cullet and Sasa plants as active ingredients. Here, food and drink includes beverages and / or food. Food and drink also includes feed. Therefore, food and drink includes feed (including pet food such as dog food and cat food), health food (including health food for animals), functional food, nutritional supplement (including nutritional supplement for animals), supplement (including supplement for animals), food for specified health use, etc. Food and drink can be rephrased as food and drink composition.

[0070] When the oral composition for animals of the present disclosure is used as a food or beverage itself or added to a food or beverage, the form of the food or beverage is not particularly limited, and may be, for example, beverages (coffee, juice, tea drinks, soft drinks such as jelly drinks, milk drinks, lactic acid bacteria drinks, yogurt drinks, carbonated drinks, etc.), spreads (custard cream, etc.), pastes (fruit paste, etc.), Western confectionery (chocolate, donuts, pies, cream puffs, gum, jelly, candy, cookies, cakes, puddings, etc.), Japanese confectionery (daifuku, mochi, manju, castella, anmitsu, yokan, etc.), frozen desserts (ice cream, popsicles, sherbet, etc.), foods (curry, beef bowls, rice porridge, miso soup, soup, meat sauce, pasta, pickles, jam, etc.), or seasonings (dressings, furikake, umami seasonings, soup bases, etc.).

[0071] When the veterinary oral composition of the present disclosure is used as a food or beverage whose tertiary function is emphasized (e.g., a health food, a functional food (functional food), a nutritional supplement, a dietary supplement, or a food for specified health uses) itself, or added to a food or beverage whose tertiary function is emphasized, the form of the food or beverage whose tertiary function is emphasized may be, in addition to the forms of the food or beverage described above, for example, plain tablets, sugar-coated tablets, granules, powder, tablets, capsules (hard capsules, soft capsules, seamless capsules, etc.), etc.

[0072] The above-mentioned foods and beverages can use the above-mentioned Tamogitake mushrooms and bamboo plants as they are, and if necessary, excipients, vitamins, minerals, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants, fragrances, stabilizers, preservatives, sustained-release regulators, surfactants, gloss agents, solubilizers, humectants, etc. can be blended.

[0073] The food and drink compositions include any food and drink that can be ingested by mammals (including humans). Examples of the food and drink compositions include dairy products, fermented foods (yogurt, cheese, etc.), beverages (coffee, juice, cocoa, tea drinks, sports drinks, soft drinks such as energy drinks, dairy drinks, lactic acid bacteria drinks, lactic acid bacteria-containing drinks, yogurt drinks, carbonated drinks, sake, Western liquor, and alcoholic beverages such as fruit wine, spreads (custard cream, etc.), pastes (fruit paste, etc.), Western confectioneries (chocolate, donuts, pies, cream puffs, chewing gum, gummy candies, jellies, candies, cookies, cakes, puddings, biscuits, etc.), frozen desserts (ice cream, popsicles, sorbets, etc.), foods (curry, beef bowls, rice porridge, miso soup, soup, meat sauce, pasta, pickles, jam, ham, sausage, bacon, etc.), and seasonings (dressings, furikake, umami seasonings, soup bases, miso, soy sauce, sauces, ketchup, oyster sauce, etc.).

[0074] The method for producing the food or drink is not particularly limited, and any known method can be used as appropriate.

[0075] The dosage unit form when used as a supplement is not particularly limited and can be selected appropriately, and examples include tablets, capsules, granules, liquids, powders, etc.

[0076] When feed is given to pets, it is called pet food. There are no particular limitations on the pet food, and examples include cat food and dog food. A pet is a non-human animal kept for the purpose of viewing or caring for others. Therefore, for example, animals raised for the purpose of shipping meat, eggs, fur, milk, etc. are usually included in livestock and distinguished from pets. However, animals raised for the purpose of working (working animals), such as police dogs and guide dogs, may be fed the same feed as pets. Even if the purpose of raising them is working, if the same feed as pets is fed to the same animal species, such feed is included in the pet food referred to in this disclosure. Furthermore, the food and drink referred to in this disclosure also includes the meanings of pet food, supplements, etc. When used for animals, the term supplement includes the meaning of animal supplements.

[0077] The food and drink products disclosed herein may contain not only Pleurotus cornucopiae and Sasa genus plants, but also Pleurotus cornucopiae and Sasa genus plants, and any optional components that are ingested as food, drink, or feed for mammals. The oral composition for animals of the present disclosure may further contain a carrier acceptable as a food or drink, pet food, or supplement. Such carriers are not particularly limited, and examples include conventionally known food additives such as preservatives, antiseptics, antioxidants, preservatives, sweeteners, dyes (coloring agents), fragrances, moisturizers, and seasonings.

[0078] The oral composition for animals of the present disclosure may be added to other foods and beverages, and can be blended with ingredients widely used in foods and beverages, pet foods, or supplements, such as grains, vegetables, fruits, meat, fish, milk, eggs, etc.

[0079] Generally, foods and beverages contain carbohydrates, proteins, minerals, fats, water, dietary fiber, etc. Most of the raw materials are animal or plant tissues, microbial cells, and processed products thereof. Processed products are products obtained by heating, drying, freeze-drying, extracting, etc., using these materials as raw materials. The series of processes for obtaining processed products can also be a combination of multiple different steps. Depending on the form of the food or drink, ingredients such as bulking agents, binders, viscosity adjusters, etc. may be added. These ingredients may be naturally derived or synthetic. As described above, when ingesting food or beverages that do not contain Pleurotus ulces and Sasa genus plants, mixing Pleurotus ulces and Sasa genus plants into the food or beverages can produce an oral composition for animals according to the present disclosure. Specifically, for example, before feeding pet food to a companion animal, the oral composition for animals of the present disclosure can be mixed with (for example, sprinkled on) the pet food and used. In addition, the food and beverage products of the present disclosure can also be obtained by adding Pleurotus cullet and a bamboo plant to the materials used for the food and beverage products. The amount of the animal oral composition relative to food and beverages is not particularly limited. For example, in the case of pet food, the amount varies depending on the amount of pet food, the type and size of the pet animal, etc., but the animal oral composition of the present disclosure can be mixed into the pet food in the amount described above.

[0080] The intake amount of food and drink can be appropriately determined depending on various conditions of the consumer, such as weight, age, sex, symptoms, etc.

[0081] The content of the oral composition for animals containing maitake mushrooms and bamboo plants added to the food and beverages disclosed herein is not particularly limited, but is typically 3 to 7 g per animal per dose, preferably 4 to 6 g per animal per day. In other words, the food and beverage products disclosed herein can be formulated with an oral composition for animals containing 0.03 to 0.07 g, preferably 0.04 to 0.06 g, of maitake mushrooms and bamboo plants per animal per day, relative to the standard daily intake of a food and beverage product or feed composition.

[0082] When the food or drink in the present disclosure is a nonessential food such as chewing gum, the dosage of the oral composition for animals containing Pleurotus cornucopius and a Sasa plant can be controlled by indicating the daily intake amount of the food according to the blended amount of the oral composition for animals containing Pleurotus cornucopius and a Sasa plant. For example, when one piece of chewing gum contains a daily dosage, it is recommended that one piece of chewing gum be ingested per day.

[0083] The foods and beverages of the present disclosure can be formulated into conventionally known forms such as tablets, orally disintegrating tablets, chewable tablets, capsules, granules, powders, and oral liquids by conventionally known methods.

[0084] When the food and beverage products of the present disclosure are made into tablets, orally disintegrating tablets, chewable tablets, or capsules, various additives for forming tablets, such as excipients such as crystalline cellulose, binders such as gelatin, corn starch, tragacanth, and gum arabic, disintegrants, lubricants such as magnesium stearate, and other nutrients, can be added.

[0085] When the food or drink of the present disclosure is intended as an oral liquid, it can be mixed with water, juice, etc.

[0086] The oral composition for animals containing Pleurotus cornucopiae and a Sasa plant according to the present disclosure can be compounded with a chewable carrier to form a chewable oral composition. A chewable carrier refers to a component that is chewed when administered to the oral cavity of an animal. The chewable carrier can be a material that is easily chewed, or a material that is not easily broken into small pieces by chewing. The chewable carrier is not particularly limited, and examples thereof include glucose, sucrose, maltose, sorbitol, xylitol, trehalose, starch, gelatin, alginic acid, alginate salts, cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, guar gum (polygalactomannan), glucomannan, xanthan gum, and carbopol.

[0087] Various types of gum bases are also included in the chewable carriers of the present disclosure. Generally, a gum base is a carrier that maintains a constant volume even when chewed in the mouth for a long period of time. The gum base is not particularly limited, and examples thereof include vegetable resin, chicle, vinyl acetate resin, ester gum, polyisobutylene, calcium carbonate, jelutong (pontianak), and the like.

[0088] When the chewable oral composition of the present disclosure is used as a pharmaceutical product, it is a chewable pharmaceutical composition, when it is provided as a food or drink, it is a chewable food product, and when the animal oral composition of the present disclosure is used as a chewable feed, it is a chewable feed composition. In addition, in order to induce chewing behavior in non-human animals, the size of the chewable oral composition can be adjusted. That is, by processing it into a size that cannot be swallowed in one bite, chewing behavior can be induced in non-human animals. Furthermore, by increasing the hardness according to the animal, more chewing behavior can be induced.

[0089] The oral composition for animals containing Pleurotus cornucopiae and a plant of the genus Sasa according to the present disclosure can also be compounded with a paste-like carrier to form a paste-like oral composition. That is, the present disclosure provides an oral composition comprising Pleurotus cornucopiae, a plant of the genus Sasa, and a paste-like carrier. Paste-like carriers include carriers having semi-solid consistency, gel-like carriers, and the like.

[0090] The paste-like oral composition is not particularly limited, and can be prepared, for example, by adding a solvent such as water to a water-soluble polysaccharide or polymer compound. Examples of water-soluble polysaccharides or polymer compounds include glucose, sucrose, maltose, sorbitol, xylitol, starch, gelatin, pectin, alginic acid, alginate salts, cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, guar gum (polygalactomannan), glucomannan, carrageenan, xanthan gum, tamarind gum, carbopol, agarose, agar, etc. In addition, polymer compounds such as polyethylene glycol and polyvinylpyrrolidone can also be incorporated as gel-like carriers into the oral composition for animals of the present disclosure.

[0091] A paste-like or gel-like oral composition for animals can be administered, for example, by applying it to tissues in the oral cavity. Oral tissues include the gums, teeth, sublingual space, buccal cavity, and buccal mucosa. For example, application to the gums is preferred because it allows direct administration to the periodontal lesion. Application to the buccal cavity is also a preferred administration method. Application of a paste-like composition to oral tissues is an administration method that can also be applied to non-human animals. As a method of administration primarily to humans, the oral composition for animals of the present disclosure can also be administered as a toothpaste. That is, a toothpaste containing Pleurotus cornucopiae and a plant of the genus Sasa is used as the oral composition for animals of the present disclosure. Of course, it goes without saying that the oral composition for animals of the present disclosure can also be administered as a toothpaste to non-human animals as long as the individual can tolerate tooth brushing.

[0092] Medicines or quasi-drugs The pharmaceuticals or quasi-drugs of the present disclosure include the above-mentioned Pleurotus cullet and Sasa plants. The above-mentioned pharmaceuticals or quasi-drugs may contain only Pleurotus ulces and Sasa plants, or may be used in combination with other medicinal ingredients listed in the Japanese Pharmacopoeia, such as vitamins and herbal medicines.

[0093] When the veterinary oral composition of the present disclosure is used as a pharmaceutical or quasi-drug itself, or added to a pharmaceutical or quasi-drug, the form of the pharmaceutical or quasi-drug is not particularly limited, and may be, for example, a plain tablet, a sugar-coated tablet, a granule, a powder, a tablet, a capsule (hard capsule, soft capsule, seamless capsule, etc.), etc.

[0094] Specifically, when preparing the oral composition for animals of the present disclosure as a pharmaceutical, Pleurotus ulces and Sasa plants can be prepared together with non-toxic carriers, diluents, or excipients acceptable for pharmaceuticals into the form of tablets (including plain tablets, sugar-coated tablets, effervescent tablets, film-coated tablets, chewable tablets, troches, etc.), capsules, pills, powders (pulverized medicines), granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including when mixed with distilled water or infusions such as amino acid infusions or electrolyte infusions at the time of use to prepare them as liquids), etc., to form a pharmaceutical formulation.

[0095] The method of administering the pharmaceutical is not particularly limited, and can be, for example, oral administration.

[0096] The dosage of the pharmaceutical can be determined appropriately depending on various conditions such as the patient's weight, age, sex, symptoms, etc.

[0097] The method for producing a pharmaceutical or quasi-drug to which the oral composition for animals of the present disclosure has been added is not particularly limited, and any known method can be used as appropriate. For example, the pharmaceutical or quasi-drug used for the above-mentioned purposes can be obtained by mixing the oral composition for animals of the present disclosure with an intermediate product or a final product in the manufacturing process of the pharmaceutical or quasi-drug.

[0098] The content of the oral composition for animals of the present disclosure in a pharmaceutical or quasi-drug may be appropriately set depending on the type of pharmaceutical or quasi-drug, etc., so that the amount of active ingredient ingested per day falls within the above-mentioned range.

[0099] The present disclosure is effective against diseases associated with the above-mentioned oral compositions for animals. [Example]

[0100] The present disclosure will be explained in more detail below using examples, but the technical scope of the present disclosure is not limited to these examples.

[0101] Example 1 (Oral Composition 1 for Animals (Combination 1)) Tamogitake extract (manufacturer: Three B Co., Ltd., concentration: approximately 10%) and bamboo grass extract (manufacturer: Toyochem Co., Ltd., concentration: approximately 50%) were diluted with water to a final concentration of 1%, and mixed for 30 minutes until uniform using a mixer (manufactured by Jonan Jido-ki Co., Ltd., product name: Automatic Viscous Liquid Filling and Packaging Machine) to obtain veterinary oral composition 1 (combination 1) (tamogitake extract: bamboo grass extract = 1:1). Hereinafter, tamogitake extract may be abbreviated as tamogitake, and bamboo grass extract may be abbreviated as bamboo grass. Furthermore, an oral composition for animals containing tamogitake and bamboo grass extract may be referred to as a combination, tamogitake extract alone may be referred to as tamogitake alone, and bamboo grass extract alone may be referred to as bamboo grass alone.

[0102] Example 2 (Oral Composition 2 for Animals (Combination 2)) Oral composition 2 for animals (combination 2) was obtained in the same manner as in Example 1, except that it was diluted with water so that the final concentration of bamboo grass was half (0.5%) (maitake mushroom extract: bamboo grass extract = 1:0.5).

[0103] Comparative Example 1 (control group) The control group received no administration.

[0104] Comparative Example 2 Sasa extract (manufacturer: Toyochem Co., Ltd., concentration: approximately 50%) was diluted with water to a final concentration of 1%, and mixed for 30 minutes using a mixer (manufactured by Jonan Jido-ki Co., Ltd., product name: automatic viscous liquid filling and packaging machine) until homogeneous, to obtain a single agent of Sasa.

[0105] Test example 1: Confirmation of effectiveness against oral diseases A total of nine Japanese hybrid cats (manufactured by Oriental Yeast Co., Ltd.) were used in an animal testing facility (Shokukan Hygiene Research Institute Co., Ltd.), and the anti-inflammatory effects of Example 1 (veterinary oral composition 1 (combination 1)), Example 2 (veterinary oral composition 2 (combination 2)), and Comparative Example 1 (control group) on gingivitis in cats were confirmed. The animals were divided into groups: six animals administered with the animal oral composition 1 of the present disclosure (Example 1: Combination 1), six animals administered with the animal oral composition 2 of the present disclosure (a combination prepared so that the bamboo component of the animal oral composition 1 was half the amount) (Example 2: Combination 2), and three animals administered as untreated controls (Comparative Example 1: control group). Furthermore, Example 1 (Combination 1) and Example 2 (Combination 2) were administered orally by forced administration through the corners of the mouth to ensure reliable administration to the animals in each administration group. The administration method and dosage were every other day, with a total of 8 packets (40 ml) per animal.

[0106] Gingival inflammation was observed by scoring the left maxillary molar (C) and the left mandibular second premolar (P2) before the start of the study (Pre) and after the eighth administration according to the modified GI score (Table 1 below) based on the Gingival Index (GI) proposed by Loe & Silness. Scoring was performed by calculating the sum of the gingivitis index (GI) of two representative teeth observed for each individual, and recording the amount of change from the value before the start of the test, which was set to 1.

[0107] FIG. 1 shows a photograph (left) of veterinary oral composition 1 (combination 1) of Example 1 before administration to a cat with severe gingivitis, and a photograph (right) of the cat after eight administrations. In addition, the changes in gingivitis index (GI) for veterinary oral composition 1 (combination 1) of the present disclosure, veterinary oral composition 2 (combination 2) of Example 2, and Comparative Example 1 (control group) are shown in Table 2 and Figure 2.

[0108] JPEG0007731613000002.jpg54170

[0109] JPEG0007731613000003.jpg42170

[0110] result As a result, as shown in Table 2 and Figure 2, it was confirmed that oral compositions 1 and 2 for animals of the present disclosure (Examples 1 and 2) reduced gingival inflammation compared to the control group (Comparative Example 1) when administered eight times every other day. In particular, Combination 1 of Example 1 (1% Pleurotus citri + 1% Sasa grass) significantly reduced gingival inflammation compared to the control group (Comparative Example 1) (p<0.05). Furthermore, Combination 1 of Example 1 (1% Pleurotus citri + 1% Sasa grass) showed a more significant effect in reducing gingival inflammation compared to Combination 2 of Example 2 (1% Pleurotus citri + 0.5% Sasa grass).

[0111] Test Example 2: Confirmation of immune regulation effects Using the above Example 1 (combination 1) and Comparative Example 2 (1% bamboo grass single agent), a test on immune regulation was carried out. Specifically, blood samples were collected from a cat with severe gingivitis before and after eight doses of Example 1 (Combination 1), and analyzed for the inflammatory cytokine feline interleukin-1β (Kingfisher, manufactured by Thermo Fisher Scientific Co., Ltd.). In addition, blood samples were collected from seven Japanese hybrid cats (manufactured by Oriental Yeast Co., Ltd.) different from those in Test Example 1 before and after eight doses of Comparison Example 2 (1% Sasa monotherapy), and feline interleukin-1β was analyzed in the same manner as above.

[0112] JPEG0007731613000004.jpg97170

[0113] result As a result, it was confirmed that the IL-1β levels in two cats with severe gingivitis, which had high levels before administration, were reduced in both individuals by administering the veterinary oral composition 1 (Example 1 (Combination 1)) of the present disclosure. In contrast, administration of Sasa alone resulted in no detectable feline interleukin-1β levels. Therefore, it was found that the veterinary oral composition 1 (Example 1 (combination 1)) of the present disclosure has a synergistic effect compared to the single agents.

[0114] Example 3 (Dog Food Composition) 5 g of the animal oral composition 1 (combination 1) of Example 1 above was mixed with approximately 50 g of dog food that was routinely given to each of the individuals 1 to 7 shown in Table 4 below to obtain dog food compositions 1 to 7, each containing the animal oral composition of the present disclosure.

[0115] Test Example 3: Bad breath suppression effect Seven dogs (aged 0.5 to 12 years) kept in ordinary households were orally fed the above dog food compositions 1 to 7, each 3 to 8 times, generally every other day (Table 4).

[0116] A questionnaire survey regarding bad breath was conducted among owners of dogs that had been administered pet food compositions 1 to 7 of the present disclosure. The question asked was, "Have you noticed any changes in your bad breath?" and participants were asked to answer one of the following questions, and the results were compiled. · Changed (there was a slight change) No change (no change observed) Deterioration The results are shown in Table 4 and FIG.

[0117] JPEG0007731613000005.jpg77170

[0118] result As a result, six owners of seven dogs tested reported "changes," i.e., a decrease in symptoms. No responses indicated "worsening." These results confirmed that administration of the veterinary oral composition of the present disclosure is effective in improving the oral environment in dogs. It was suggested that bad breath can be suppressed by suppressing inflammation and the associated reduction in volatile sulfur compounds due to a decrease in periodontal pathogens. In addition, it was confirmed that oral administration via feeding, rather than forced oral administration via the corners of the mouth, can also exert an oral care effect.

[0119] Example 4 An oral composition for animals of the present disclosure was produced in the same manner as in Example 1. After production, it was stored in a cool, dark place until use.

[0120] Comparative Example 2 A single agent of bamboo grass (final concentration 1%) was prepared and then stored in a cool, dark place until use.

[0121] Test Example 4: Synergistic Effect A total of 12 Japanese hybrid cats (manufactured by Oriental Yeast Co., Ltd.) were used in the animal testing facility (Shokukan Hygiene Research Institute Co., Ltd.). The animals were divided into groups of 6 to be administered with the animal oral composition 2 of the present disclosure (Example 4 (combination 1) administration group) and 6 to be administered with Sasa alone (Comparative Example 2 (Sasa alone) administration group). Each drug was administered orally, with four packets per week as a guideline, by forced administration through the corners of the mouth to ensure that each drug was administered to each individual in each treatment group. Each drug was administered eight times.

[0122] Gingival inflammation was observed by scoring the left maxillary molar (C) and left mandibular second premolar (P) according to the same gingivitis index as in the Examples before the start of the test (Pre), after the eighth administration, and the next day. Scoring was performed by calculating the sum of the gingivitis index (GI) of two representative teeth observed for each individual, and recording the amount of change from the value before the start of the test, which was set to 1.

[0123] The changes in gingivitis index (GI) for Example 4 (combination 1) and Comparative Example 2 (sasa monotherapy) are shown in Table 5 below and FIG.

[0124] JPEG0007731613000006.jpg37170

[0125] result As a result, as shown in Table 5 and Figure 4, the oral composition for animals containing 1% maitake mushroom and 1% bamboo grass (Example 4) had a significant effect in reducing gingivitis compared to bamboo grass alone (Comparative Example 2). Therefore, it was confirmed that the oral composition for animals of Example 4, which is a combination of maitake mushroom and bamboo, has synergistic effects such as down-regulation of inflammatory immune responses.

[0126] Example 5 Oral composition 5 for animals of the present disclosure was produced in the same manner as in Example 1. After production, it was stored in a cool, dark place until use.

[0127] Test Example 5: Confirmation of effect on stool odor 5 g of the animal oral composition 5 (combination) of Example 5 above was mixed with the dog food or cat food (equivalent to a normal single feeding) that was routinely given to seven dogs (0.5 to 12 years old) and five cats (2 to 12 years old) kept in ordinary households, to obtain pet food compositions 8 to 19 containing the animal oral composition of the present disclosure. Pet food compositions 8 to 19 were orally administered to the corresponding dogs (individuals 16 to 22) or cats (individuals 23 to 27) a total of 3 to 8 times, generally every other day (Table 6).

[0128] A questionnaire survey regarding fecal odor was conducted among owners of dogs and cats that had been administered pet food compositions 8 to 19 of the present disclosure. The question asked was, "Have you noticed any change in stool odor?" and participants were asked to answer one of the following questions, and the results were compiled. · Changed (there was a slight change) No change (no change observed) Deterioration The results are shown in Table 6, Figures 5 and 6.

[0129] JPEG0007731613000007.jpg96170

[0130] result As a result, as shown in Table 6 and Figure 5, the owners of 6 out of 7 dogs tested answered that there was a "change," that is, a decrease in the condition. No one answered that the condition had "worsened." Furthermore, as shown in Table 6 and Figure 6, owners of four out of five cats tested responded that there was a "change," that is, that there was a decrease. No owners responded that there was a "worsening" change. These test results confirmed that administration of the veterinary oral composition of Example 5 not only reduced gingivitis in cats as described in Test Examples 1 and 2, but also suppressed fecal odor in dogs and cats. This suggests that oral administration of Pleurotus cornucopiae and Sasa bamboo improved the intestinal environment. This finding indicates that the oral composition for animals of the present disclosure can contribute not only to improving the oral environment but also to improving the intestinal environment, and may lead to improved immunity. Furthermore, the oral composition for animals of the present disclosure was found to improve the lustre of the coat of the entire body of the animal. In particular, dog No. 21 clearly had a lustrous coat.

Claims

1. An oral composition for companion animals comprising Pleurotus cornucopiae and a plant of the genus Sasa, An oral composition for companion animals for use in treating gingivitis.

2. The oral composition for companion animals according to claim 1, wherein the maitake mushroom is an extract of maitake mushroom.

3. The oral composition for companion animals according to claim 1, wherein the Sasa genus plant comprises Sasa senanensis and / or Sasa kurilensis.

4. The oral composition for companion animals according to claim 1, wherein the Sasa plant is an extract of a Sasa plant.

5. The oral composition for companion animals according to claim 1, wherein the content of the Sasa plant is 80 to 120 parts by mass per 100 parts by mass of Pleurotus pilchardus.

6. The oral composition for companion animals according to claim 1, which is for immunomodulation.

7. The oral composition for companion animals according to claim 6, wherein the immunomodulation is caused by suppressing the production of inflammatory cytokines.

8. The oral composition for companion animals according to claim 7, wherein the inflammatory cytokine is interleukin-1β (IL-1β).

9. The oral composition for pets according to claim 1, which is for treating bad breath or improving the intestinal environment.

10. The oral composition for pets according to claim 1, which is used to suppress the odor of excrement.

11. The oral composition for companion animals according to claim 1, which is for use in foods and beverages, cosmetics, pharmaceuticals, or quasi-drugs.

12. A food and drink composition for pets, which is for treating gingivitis and contains the oral composition for pets according to claim 1.

13. A pet food composition for treating gingivitis, comprising the oral composition for pets according to claim 1.

14. A pet food composition for companion animals for treating gingivitis, comprising the oral composition for companion animals according to claim 1.

15. A pet medicine or quasi-drug for treating gingivitis, comprising the oral composition for pets according to claim 1.

Images